Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 1 of 1

Publication Record


Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Lloyd A, Penson D, Dewilde S, Kleinman L
(2008) Prostate Cancer Prostatic Dis 11: 153-9
MeSH Terms: Adenocarcinoma, Aged, Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Choice Behavior, Cross-Sectional Studies, Diarrhea, Drug Administration Schedule, Drug Costs, Drug Therapy, Erectile Dysfunction, Flutamide, Gynecomastia, Health Surveys, Hematuria, Humans, Life Expectancy, Male, Middle Aged, Nitriles, Patient Acceptance of Health Care, Patient Satisfaction, Prostatic Neoplasms, Tosyl Compounds
Show Abstract · Added March 5, 2014
Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life. The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire. Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey. As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important. Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
0 Communities
1 Members
0 Resources
25 MeSH Terms